Metformin slows intestinal glucose absorption in type 2 diabetes, irrespective of the timing of its administration.
作者信息
Borg Malcolm J, Xie Cong, Chen Chang, Bound Michelle J, Grivell Jacqueline, Huang Weikun, Jones Karen L, Horowitz Michael, Rayner Christopher K, Wu Tongzhi
机构信息
Adelaide Medical School and Centre for Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, South Australia, Australia.
Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
出版信息
Diabetes Obes Metab. 2025 Sep;27(9):5370-5372. doi: 10.1111/dom.16570. Epub 2025 Jun 24.
Abstract
摘要
相似文献
1
Metformin slows intestinal glucose absorption in type 2 diabetes, irrespective of the timing of its administration.
Diabetes Obes Metab. 2025 Sep;27(9):5370-5372. doi: 10.1111/dom.16570. Epub 2025 Jun 24.
2
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2.
3
Comparative efficacy of GLP-1 RAs/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes according to baseline use of metformin: a systematic review and meta-analysis of randomized controlled trials.
Eur J Med Res. 2025 Jan 7;30(1):13. doi: 10.1186/s40001-024-02241-4.
4
Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes.
Diabetes Obes Metab. 2017 Feb;19(2):290-293. doi: 10.1111/dom.12812. Epub 2016 Nov 21.
5
Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis.
Acta Diabetol. 2021 Jan;58(1):5-18. doi: 10.1007/s00592-020-01542-4. Epub 2020 Jun 8.
6
The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus-A Systematic Review.
Int J Mol Sci. 2023 Apr 13;24(8):7184. doi: 10.3390/ijms24087184.
7
Repurposing Metformin for Vascular Disease.
Curr Med Chem. 2023;30(35):3955-3978. doi: 10.2174/0929867329666220729154615.
8
The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: A systematic review and meta-analysis.
Br J Clin Pharmacol. 2022 Aug;88(8):3627-3637. doi: 10.1111/bcp.15344. Epub 2022 Apr 17.
9
GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis.
PLoS One. 2019 Jun 25;14(6):e0217701. doi: 10.1371/journal.pone.0217701. eCollection 2019.
10
Combined effects of Yupingfeng and metformin on blood glucose levels and intestinal tissue in high-fat diet-induced type 2 diabetic rats.
Front Endocrinol (Lausanne). 2025 Jul 23;16:1532560. doi: 10.3389/fendo.2025.1532560. eCollection 2025.
引用本文的文献
1
Comparative effectiveness of tirzepatide versus bariatric metabolic surgery in adults with metabolic-associated steatotic liver disease and obesity: a multi-institutional propensity score-matched study.
Hepatol Int. 2025 Jul 16. doi: 10.1007/s12072-025-10857-9.
本文引用的文献
1
Effects of Metformin on Postprandial Blood Pressure, Heart Rate, Gastric Emptying, GLP-1, and Prevalence of Postprandial Hypotension in Type 2 Diabetes: A Double-Blind Placebo-Controlled Crossover Study.
Diabetes. 2025 Apr 1;74(4):611-618. doi: 10.2337/db24-0830.
2
Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study.
Diabetologia. 2024 Jul;67(7):1260-1270. doi: 10.1007/s00125-024-06131-6. Epub 2024 Apr 1.
3
Enteroendocrine Hormone Secretion and Metabolic Control: Importance of the Region of the Gut Stimulation.
Pharmaceutics. 2020 Aug 21;12(9):790. doi: 10.3390/pharmaceutics12090790.
4
Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids.
Diabetes Obes Metab. 2020 Feb;22(2):141-148. doi: 10.1111/dom.13869. Epub 2019 Oct 7.
5
Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes.
Diabetes Obes Metab. 2019 Mar;21(3):640-647. doi: 10.1111/dom.13567. Epub 2018 Nov 21.
6
Metformin: historical overview.
Diabetologia. 2017 Sep;60(9):1566-1576. doi: 10.1007/s00125-017-4318-z. Epub 2017 Aug 3.
7
New insights into the anti-diabetic actions of metformin: from the liver to the gut.
Expert Rev Gastroenterol Hepatol. 2017 Feb;11(2):157-166. doi: 10.1080/17474124.2017.1273769. Epub 2016 Dec 26.
8
Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes.
Diabetes Obes Metab. 2017 Feb;19(2):290-293. doi: 10.1111/dom.12812. Epub 2016 Nov 21.
9
Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials.
Diabetologia. 2016 Aug;59(8):1645-54. doi: 10.1007/s00125-016-3992-6. Epub 2016 May 23.
10
Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?
Diabetes Res Clin Pract. 2014 Oct;106(1):e3-6. doi: 10.1016/j.diabres.2014.08.004. Epub 2014 Aug 12.
Zotero 插件